The protein and mRNA expression levels of occludin, ZO-1, and claudin-1 decreased in the model group, but tended to be higher in each dose group of the PAD and LM group, with the most notable changes observed in the PAD-H group (Fig 7A, 7B). Here, CLDN1 is linked to peripheral arterial disease.